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Currently, early gastrointestinal cancers are treated endoscopically, as long as there are no 
lymph node metastases. However, once a gastrointestinal cancer invades the submucosal 
layer, the lymph node metastatic rate rises to higher than 10%. Therefore, surgery is still the 
gold standard to clean regional lymph nodes containing possible metastases. Here, to avoid 
prophylactic surgery, we propose a less-invasive biological ablation of lymph node metastasis 
in submucosally invaded gastrointestinal cancer patients. We have established an orthotopic 
early rectal cancer xenograft model with spontaneous lymph node metastasis by implantation 
of green fluorescent protein (GFP)-labeled human colon cancer cells into the submucosal 
layer of the murine rectum. A solution containing telomerase-specific oncolytic adenovirus 
was injected into the peritumoral submucosal space, followed by excision of the primary 
rectal tumors mimicking the endoscopic submucosal dissection (ESD) technique. Seven days 
after treatment, GFP signals had completely disappeared indicating that sentinel lymph node 
metastasis was selectively eradicated. Moreover, biologically treated mice were confirmed to 
be relapse-free even 4 weeks after treatment. These results indicate that virus-mediated 
biological ablation selectively targets lymph node metastasis and provides a potential 
alternative to surgery for submucosal invasive gastrointestinal cancer patients. 
 
  




Due to recent advances in endoscopic technology, early gastrointestinal cancers, which are 
defined as those that invade no more deeply than the submucosa, are treated endoscopically
1-3
. 
Endoscopic submucosal dissection (ESD) or local tumor excisions that allow en bloc 
resection, which lead to more precise histological evaluation and more potential for cure, are 
considered clinically relevant for early gastrointestinal cancer. A complete local resection of 
in situ or intramucosal tumor is acceptable as a curative treatment due to little risk of lymph 
node metastasis
4-7
. However, lymph node metastasis is typically found in submucosal 
invasive gastrointestinal cancer such as esophageal, gastric and colorectal cancer, at an 
approximate frequency of greater than 10%
8-11
.  Since it is hard to determine submucosally 
invaded lesions with the risk of lymph node metastasis without pathological evaluation, these 
patients are treated surgically to remove possibly metastasized lymph nodes, even though 
primary early gastrointestinal cancer itself is technically resectable with ESD. This means 
that most submucosal invasive gastrointestinal cancer patients, who are node-negative, 
routinely undergo unnecessary surgery. Thus, a less invasive way to selectively treat lymph 
node metastasis would benefit these patients by allowing them to avoid a prophylactic 
surgery. 
Sentinel lymph node metastasis represents the initial spread of malignant tumors from 
the primary site. Metastatic lymph nodes as well as migrating tumor cells in the draining 
lymph vessels have to be treated to prevent recurrence and, therefore, anticancer agents that 
spread over the regional lymphatic area are required. For sentinel lymph node mapping, 
submucosal injection of a visible dye such as methylene blue or indocyanine green (ICG) 
allows an adequate regional diffusion in the lymphatic area
12
. It has also been reported that 
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human adenovirus can be effectively transported into the lymphatic circulation in murine 
models
13,14
. Oncolytic viruses that selectively replicate in tumor cells and lyse infected cells 
have been developed as anticancer agents
15-18
. These viruses are designed to induce virus-
mediated lysis of infected cells after selective viral replication within the tumor cells.  
In the present study, we evaluated whether a telomerase-dependent, tumor-killing 
replicating adenoviral agent (OBP-301) that was administered submucosally prior to the 
primary tumor resection could purge lymph node metastasis in an orthotopic early rectal 
cancer xenograft model with spontaneous lymph node metastasis. The steps of this procedure 
mimic the procedures of ESD for gastrointestinal cancer in the clinical setting. The successful 
elimination of sentinel lymph node metastasis indicates that concurrent submucosal injection 
of OBP-301 and endoscopic tumor removal might be an epoch-making therapeutic alternative 




In vitro cytopathic effect of the virus towards human colorectal cancer cells 
OBP-301 (Telomelysin) is an attenuated adenovirus that drives the E1A and E1B genes under 
the human telomerase reverse transcriptase (hTERT) promoter and is capable of killing 
human epithelial as well as mesenchymal malignant cells in a telomerase-dependent manner 
(Supplementary Figure S1a)
19-21
. To assess the cytopathic effect (CPE) of OBP-301 
towards human colorectal cancer cells, green fluorescent protein (GFP)-labeled HCT-116 or 
Colo205 cells were infected either with OBP-301 or with a replication-deficient, E1-deleted 
adenovirus, dl312 and were photographed using a fluorescent microscope after viral infection. 
Both HCT-116-GFP and Colo205-GFP cells infected with OBP-301 at an MOI of 10 
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exhibited rapid cell death by 72 h after virus infection, whereas cells treated with the same 
MOI of dl312 or with PBS showed no morphological change (Figure 1a and Supplementary 
Figure S2). The XTT cell viability assay also demonstrated that OBP-301 infection induced 
cell death in a dose-dependent fashion both in HCT-116-GFP and Colo205-GFP cells, 
whereas infection with dl312 did not show significant CPE at MOIs of up to 100 (Figure 1b). 





Sentinel lymph node metastasis in an orthotopic rectal cancer xenograft model 
A submucosally invaded early rectal tumor model was established by inoculating HCT-116-
GFP or Colo205-GFP human colorectal cancer cells orthotopically into athymic nu/nu mice. 
Seven days after implantation of GFP-labeled cancer cells into the submucosal layer of the 
rectum, the mice developed tiny rectal tumors that were clearly visible by fluorescence 
imaging of GFP signals (Figure 2a, Supplementary Figure S3 and S5a). Histopathological 
examination of the excised primary rectal tumors showed a submucosal tumor formation 
composed of implanted cancer cells with no muscularis propria invasion. Examination under 
high magnification showed cancer cell-filled lymphatic vessels in the submucosal layer 
(Figure 2b). The metastatic status of regional lymph nodes was easily assessed at laparotomy, 
by detection of cancer cell-derived GFP signals in the lymph node (Figure 2c, d). A series of 
experiments confirmed that percent metastasis to the sentinel lymph node on day 7 after 
tumor cell inoculation in mice implanted with HCT-116-GFP and Colo205-GFP was 78.5% 
(33/42) and 62.5% (25/40), respectively.  
 
Viral trafficking to lymph nodes and selective replication in metastatic foci 
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The lymphatic system is a major pathway for the metastatic spread of cancers as well as for 
the regional distribution of biological mediators including fluids, proteins, chemicals, cells 
and drugs. Prior to injection of virus, we first assayed the ability of an injected solution to 
reach the draining lymph nodes. For this purpose, we investigated the diffusion pattern of a 
1% indigo carmine blue dye solution that was peritumorally injected into the submucosal 
space of the rectum in the orthotopic rectal cancer xenografts. Intense blue staining was 
detected in regional lymph nodes as early as 1 minute after injection of the dye, indicating 
that an injected solution could rapidly enter the lymphatics and spread to the draining lymph 
nodes (Supplementary Figure S4).  
To verify that virus could move to regional lymph nodes and further infect tumor cells 
in these nodes after peritumoral injection into the submucosal space of the mouse rectum, we 
used RFP-labeled HCT-116 cells and GFP-expressing OBP-401 (TelomeScan). OBP-401 
was constructed by inserting the GFP gene under the control of the cytomegalovirus 
promoter at the deleted E3 region of OBP-301
13,22
 (Supplementary Figure S1). When RFP-
expressing sentinel lymph node metastases were established, mice were peritumorally 
injected with OBP-401 into the rectal submucosal space. Six days after OBP-401 injection, 
virus-induced GFP expression was detected in the sentinel lymph nodes by fluorescence 
imaging. The merged images showed that the viral GFP signals were coincident with RFP 
fluorescence of metastatic foci in sentinel lymph nodes (Figure 3a, b). Moreover, 
immunohistochemical staining for adenoviral E1A protein demonstrated that the E1A protein 
was selectively expressed in the metastatic area in lymph nodes, confirming the presence of 
replicating OBP-301 in metastatic tumor cells (Figure 3c). These results indicate that, after 
injection into the submucosal space, OBP-301 can traffic through the lymphatics to the 
regional lymph nodes and selectively replicate in cancer cells in metastatic lymph nodes. 
Kikuchi et al., page 8 
 
 
Virus-mediated biological ablation of metastatic foci in regional lymph nodes 
We next examined whether peritumoral submucosal injection of OBP-301 followed by 
primary tumor resection could ablate lymph node metastasis in the orthotopic submucosally 
invaded rectal cancer xenografts. Seven days after inoculation with HCT-116-GFP human 
colorectal cancer cells, mice that had successfully established GFP-expressing lymph node 
metastasis were selected by fluorescence imaging at laparotomy, and were further studied 
(Figure 4a). When primary rectal tumors were surgically removed, a solution containing 
OBP-301 (1 × 10
9 
PFU/30µl PBS) was peritumorally injected into the submucosal space as a 
fluid cushion. This fluid cushion was used to lift up the tumors in order to precisely preserve 
the rectal muscular layer (Supplementary Figure S5). These procedures mimicked the 
standard ESD technique in humans. Seven days after tumor resection, a second-look 
laparotomy was performed to assess tumor progression in the lymph nodes. Mice treated with 
PBS (30 µl), cisplatin (30 µl of concentrated original solution; 30 µg), or dl312 (1 × 
10
9
PFU/30µl PBS) showed more intense GFP expression, and GFP expression over a wider 
area in metastatic lymph nodes, whereas GFP signals were undetectable in mice that had 
received OBP-301, indicating the complete eradication of metastatic tumor cells in these 
mice (Figure 4b).  
 To more precisely quantify virus-mediated effects on lymph node metastasis, 
fluorescence intensities were measured using image analysis software.  Pre-injection of OBP-
301 prior to primary tumor resection significantly reduced GFP signals compared to the other 
groups in both HCT-116 and Colo205 xenograft models (Figure 5a). Quantification of the 
amounts of human cancer cells in mouse lymph nodes by using a highly sensitive real-time 
PCR method that targets human Alu sequences also demonstrated that OBP-301 completely 
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eradicated metastatic human cancer cells (Figure 5b). Furthermore, lower viral doses (1 × 
10
7
 or 1 × 10
6 
PFU/30µl PBS) failed to eliminate GFP fluorescence, indicating that these 
virus-mediated purging effects on metastatic lymph nodes were dose-dependent (Figure 5c).   
 
Sustained metastatic tumor eradication by virus-mediated biological ablation 
Finally, to assess if OBP-301-mediated biological ablation exerted prolonged antitumor 
effects, metastatic lymph nodes were visualized at laparotomy at 1 and 4 weeks after 
treatment using fluorescence imaging. In mice that received PBS or dl312, all metastatic 
lymph nodes grew larger in a time-dependent manner, although the magnitude of the 
enlargement varied between individual mice.  Pre-injection of cisplatin also could not affect 
tumor progression in the lymph nodes (Supplementary Figure S6). On the other hand, mice 
pretreated with OBP-301showed no GFP fluorescence for at least 4 weeks after primary 
tumor resection (Figure 6 and Supplementary Figure S6). Histopathological examination 
confirmed that virally purged lymph nodes were relapse-free (data not shown). These results 
suggest that submucosal pre-injection of OBP-301 followed by primary tumor resection 




The standard of care for treatment of intramucosal neoplastic lesions of the esophagus, 
stomach and colorectum is now a patient-friendly ESD that enables en-block resection of 
cancerous lesions regardless of size, since statistically intramucosal tumors rarely metastasize 
to the lymph node
2,23-25
.  However, when tumors penetrate slightly deeper into the 
submucosal layer, the incidence of nodal metastasis appears to increase significantly and, 
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therefore, these patients are referred for complementary surgery with regional lymph node 
dissection
10,11,26
. Here, we describe a more effective and less invasive biological management 
for lymphatic metastasis that uses the telomerase-specific, replication-selective, oncolytic 
adenovirus OBP-301 and that employs submucosally invaded early rectal cancer  xenograft 
mouse models. In detail, in place of surgical lymphadenectomy we used a solution containing 
a tumor-killing virus as a submucosal cushioning agent before resection of the primary tumor. 
From a clinical viewpoint, this new, simple, and robust strategy is a more realistic and 
promising bench-to-bedside translation than prophylactic surgery for ablation of potential 
lymph node metastases in early gastrointestinal cancer patients. 
 Overexpression of telomerase, which is a ribonucleoprotein enzyme complex that is 
responsible for the complete replication of chromosomal ends, is thought to play a key role in 
the infinite reproduction of cancer cells
27,28
. We constructed a telomerase-specific replicating 
adenovirus, OBP-301, in which the hTERT promoter element drives expression of the E1 
genes that are essential for adenoviral replication
19
. As hTERT is the catalytic subunit of 
telomerase, OBP-301 shows tumor-specific intracellular viral replication that is regulated by 
hTERT transcriptional activity in human tumors
19-21
. Viral yields correlated well with hTERT 
mRNA expression in human cancer cell lines
13,22
, although there was no significant 
correlation between hTERT mRNA expression and the cytopathic activity of OBP-301
21
. It 
has been reported that the hTERT promoter could be applied to induction of transgene 
expression in syngeneic tumors in mice
29
. We also previously confirmed that a hTERT 
promoter-driven tumor killing adenovirus could replicate in murine colorectal cancer cells 
such as Colon-26 in vitro and in vivo
13
. These findings suggest that OBP-301 can replicate in 
murine as well as in human tissues, when telomerase is activated.  Thus, the submucosally 
invaded orthotopic early rectal cancer xenograft model, which develops spontaneous lymph 
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node metastasis, is a suitable translational animal model for simulation of the in vivo behavior 
patterns of this virus.  
The lymphatic system plays a crucial role in initial lymphatic dissemination of human 
cancer cells and subsequent development of lymph node metastases. In addition to the pre-
existing lymphatic network, it is well known that new lymphatic vessels can be generated 
from pre-existing ones by tumor-secreting mediators such as vascular endothelial growth 
factors (VEGF) and angiopoietins
30
. This tumor-induced lymphangiogenesis is often 
associated with structural and functional abnormalities of the lymphatic vasculature, which 
are analogous to the aberrations of tumor blood vessels
31
. Although lymphatic vessels began 
to show abnormalities even in the early stages of carcinogenesis, advanced tumors have more 
compressed and nonfunctional lymphatics presumably due to tumor infiltration
32
.  The 
lymphatic system also provides a route for the delivery of therapeutic molecules including 
biological agents. We have shown that OBP-301 virus injected into the space under the 
orthotopically xenografted early rectal cancer could easily reach regional lymph nodes with 
normal lymphatic flow; however, a complex and impaired lymphatic network in more 
advanced tumors might disturb an optimal distribution of therapeutics into the regional 
lymphatic area. Therefore, early-stage cancer patients who potentially have micro-lymph 
node metastasis might be an appropriate target for locoregional therapy through the lymphatic 
system.   
The standard procedures for ESD, which include marking outside the lesion, injection 
of various submucosal solutions, circumferential incision into the mucosa and direct 
dissection of the submucosal layer, have been established
33
. As submucosal dissection with 
simultaneous hemostasis causes destruction of the normal lymphatic network, administration 
of therapeutic molecules prior to complete removal of neoplastic lesions is the ideal time to 
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deliver these molecules over the locoregional lymphatic area including the sentinel lymph 
nodes. The use of submucosal injection to isolate the target lesion is considered to be 
essential for a successful ESD. In addition to normal saline, many types of solutions such as 
glycerol, dextrose water and hyaluronic acid have been applied clinically
34
. The key aspect of 
our study is that a solution containing tumor-killing virus was used as a submucosal cushion 
and, therefore, the virus delivery could be easily adapted to the standard ESD procedures. 
Moreover, we found that submucosally injected dye could rapidly enter the lymphatic flow 
and spread to the draining lymph nodes, indicating a potential for extension of the purging 
effects of the viruses beyond the sentinel lymph nodes.  
Submucosal injection of OBP-301 prior to ESD-mimicking resection of submucosally 
invaded primary tumors resulted in complete inhibition of metastatic outgrowth on the 
draining lymph nodes in a dose-dependent manner.  Replicating viruses in metastatic foci of 
the sentinel lymph nodes could be visualized using dual-color in vivo imaging. Preclinical 
studies have demonstrated that the antitumor efficiency of OBP-301 strongly depends on its 
infectivity towards tumor cells, which varies among tumor types
21,35
. However, a dose-
titration study indicated that OBP-301 at 10
7 
PFU, which is 2 logs lower than the optimal 
concentration for mice (1 × 10
9 
PFU/mouse), could still effectively suppress lymph node 
metastasis, suggesting that the use of higher doses of OBP-301 could potentially overcome 
the varied sensitivity of tumor cells to OBP-301. The safety profile of OBP-301 itself after 
intratumoral delivery has already been confirmed up to 1 × 10
12 
virus particles (vp) (1 × 10
11 
PFU) in a phase I clinical trial for various types of solid tumors
36
. Furthermore, an 
investigator-driven clinical study of OBP-301 in combination with radiotherapy for 
esophageal cancer is currently ongoing in our hospital without any severe dose-limiting 
toxicity. Therefore, a 2-log-higher dose of OBP-301 could be available in humans for 
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monotherapy as well as for combination therapy. In addition, analysis of autopsied patients in 
our previous trial showed that a replication-defective adenoviral vector can persist in 
proximal lymph nodes for approximately 5 months after intratumoral injection
37
. Indeed, 
although metastatic lymph nodes grew in mice that received cisplatin, which is a broadly 
used anticancer drug, no recurrence was observed in OBP-301-treated mice in which lymph 
node metastasis had been eradicated, suggesting a long-term surveillance activity of OBP-301.  
In conclusion, we have demonstrated that the telomerase-specific replication-selective 
adenovirus OBP-301 can be delivered into neoplastic foci in regional lymph nodes after 
submucosal injection at the time of primary tumor dissection and effectively ablate lymph 
node metastasis in an early gastrointestinal cancer model. We previously reported that 
metastatic tumor cells in the lymph nodes apparently unexpectedly increased after surgical 
removal of invasive rectal tumors, presumably due to excessive damage to the host
38
; 
however, less-invasive submucosal dissection of tumors did not affect the incidence of lymph 
node metastasis. The administration of OBP-301 by inclusion in the standard ESD procedures 
is a revolutionary treatment option for early gastrointestinal cancer patients, which avoids 
impairing the quality of life that occurs due to surgery for prophylactic lymphadenectomy. 
Moreover, clinical morbidity of lymphedema particularly in breast cancer axillary node 
dissection is of significant consequence. Our strategy may have a potential for clinical 
advantages in other oncologic fields.  
 
MATERIALS AND METHODS 
 
Cell lines and recombinant adenoviruses. The human colorectal cancer cell lines HCT-116-
GFP and Colo205-GFP, which express the GFP gene, and HCT-116-red fluorescent protein 
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(RFP) cells, which express the RFP gene, were established previously
39-42
, and were routinely 
cultured in RPMI 1640 medium supplemented with 10% FBS. The recombinant replication-
selective, tumor-specific adenovirus vector OBP-301 (Telomelysin), in which the hTERT 
promoter element drives the expression of E1A and E1B genes linked with an internal 
ribosome entry site, was previously constructed and characterized
19-21
 (Supplementary 
Figure S1a). OBP-401 (TelomeScan) is a telomerase-specific, replication-competent 
adenovirus variant in which the replication cassette and GFP gene under the control of the 
cytomegalovirus promoter were inserted into the E3 region for monitoring of viral 
replication
13,22
 (Supplementary Figure S1b). The E1A-deleted adenovirus vector lacking a 
cDNA insert (dl312) was also used as a control vector. Viruses were purified by 
ultracentrifugation using CsCl step gradients. Viral titers were determined by a plaque-
forming assay using 293 cells, and the virus was stored at −80 °C. 
 
Cell viability assay. HCT-116-GFP and Colo205-GFP cells were seeded on 96-well plates at 
a density of 1 × 10
3 
cells/well 18-20 h before viral infection. The cells were then infected 
with OBP-301or control dl312 at a multiplicity of infection (MOI) of 0, 1, 5, 10, 50 or 100 
plaque forming units (PFU)/cell. Cell viability was determined on days 1, 2, 3 and 5 after 
virus infection using the Cell Proliferation Kit II (Roche Molecular Biochemicals, 
Indianapolis, IN), which is based on a sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-
bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate (XTT) assay, according to the 
manufacturer’s protocol. 
 
Animal experiments. The experimental protocol was approved by the Ethics Review 
Committee for Animal Experimentation of our institution. Six to eight-week old female 
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BALB/c nude mice (Clea Japan Tokyo, Japan) were used in this study. All animal procedures 
were performed under anesthesia using s.c. administration of a ketamine mixture (100 mg/kg 
ketamine HCL, 7 mg/kg xylazine HCL). 
 Mice were anesthetized and placed in a supine position. Both the dorsal vaginal wall 
and the ventral ano-rectal wall were cut at a length of 7 mm to expose the rectal mucosa for 
easy operation. To develop a submucosally invaded orthotopic rectal cancer model, HCT-
116-GFP, Colo205-GFP or HCT-116-RFP human colon cancer cells (1.5 × 10
6
 cells/mouse) 
suspended in a mixture of 15 µl of PBS and 15 µl of Matrigel (BD Biosciences, San Jose, 
CA) were slowly injected into the submucosal layer of the rectum using a 30-gauge needle 
(Supplementary Figure S3). Seven days later, after fluorescent signals were confirmed in 
the sentinel lymph nodes at laparotomy, a 30 µl-solution containing OBP-301, OBP-401 or 
dl312 at the indicated doses was peritumorally injected into the submucosal space as a fluid 
cushion. The tiny GFP- or FRP-positive rectal tumors were then surgically removed.  
For pathological evaluation of lymph node metastasis, mice were sacrificed and all 
para-aortic or iliac lymph nodes were isolated and were stained with hematoxylin and eosin 
or were immunohistochemically analyzed. 
 
In vivo fluorescence imaging. To monitor the outgrowth of the primary tumors and the 
metastatic lymph nodes, in vivo fluorescence images were taken at laparotomy using an 
Olympus SZX16 microscope and a DP71 camera (Olympus, Tokyo, Japan). Images were 
processed for contrast and brightness with the use of Adobe Photoshop software (Adobe). 
Green fluorescence intensity was analyzed using Image J software for the quantification of 
lymph node metastasis. For long-term evaluation, abdominal images were serially obtained 
and quantified.  
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Quantitative real-time PCR analysis. We previously established a highly sensitive 
quantitative assay that targets a human-specific Alu sequence in order to quantify lymph node 
metastasis in mice. We used this previously described assay in the present study to measure 
the numbers of metastatic human tumor cells in mouse lymph nodes 
38
. Briefly, genomic 
DNA was extracted from harvested lymph node tissues and analyzed by the quantitative real-
time PCR assay using a set of human Alu primers (sense: 5’-CTG AGG TCA GGA GTT 
CGA G-3’; and antisense: 5’-TCA AGC GAT TCT CCT GCC-3’).  We also amplified the 
mouse GAPDH genomic DNA sequence using mouse GAPDH primers (sense: 5’-CCA CTC 
TTC CAC CTT CGA T-3’; and antisense: 5’-CAC CAC CCT GTT GCT GTA-3’). The 
number of metastatic tumor cells in mouse lymph nodes is defined as the Alu/GAPDH ratio 
relative to that of the PBS-treated sample (PBS = 1). 
 
Immunohistochemistry. For histological studies, rectal tumors and lymph nodes were 
removed and placed into buffered formalin for 24 h at room temperature. All of the tissues 
were subsequently processed through alcohol dehydration and paraffinization. Tissues were 
embedded in paraffin and sectioned for hematoxylin-eosin staining and also for 
immunohistochemical examination. After deparaffinization and rehydration, antigen retrieval 
was performed by microwave irradiation in 10 mM citrate buffer (pH 6.0). Following 
quenching of endogenous tissue peroxidase, tissue sections were incubated with mouse anti-
adenovirus type 5 E1AmAb (BD Biosciences). The sections were then incubated using the 
Histofine Mouse Stain Kit (Nichirei Biosciences, Tokyo, Japan) for 10 min at 25 °C to block 
nonspecific reactivity with mouse serum. Immunoreactive signals were visualized by using a 
3,39-diaminobenzidine tetrahydrochloride solution, and the nuclei were counterstained with 
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hematoxylin. Signals were viewed under a microscope (BX50; Olympus). 
 
Statistical analysis. We used Student’s t-test to identify statistically significant differences 
between groups. All data are expressed as means ± SD. P values less than 0.05 were 
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Figure 1 Cytopathic effect of OBP-301 on human colorectal cancer cell lines. (a) HCT-
116-GFP cells were infected with replication-deficient adenovirus dl312 or OBP-301 at a 
multiplicity of injection (MOI) of 10. Cell morphology and GFP expression were evaluated at 
the indicated time points by phase-contrast (top panels) and fluorescence (bottom panels) 
microscopy, respectively. Magnification: × 200. Scale bar, 200 µm. (b) HCT-116-GFP and 
Colo205-GFP cells were infected with OBP-301 or dl312 at the indicated MOIs and cell 
survival was quantified over 5 days using the XTT assay. The cell viability of a mock-treated 
group on each day was considered 100% and the percent cell viability was calculated. Data 
are means ± SD. Statistical significance was defined as p < 0.05 (single asterisk). 
 
Figure 2 Submucosally invaded orthotopic xenografts of human colorectal cancer cells 
and subsequent development of sentinel lymph node metastasis. HCT-116-GFP human 
colorectal cancer cells (1.5 × 10
6
 cells/mouse) were submucosally inoculated into the rectum 
of nude mice. (a) Macroscopic appearance of an HCT-116-GFP rectal tumor at 7 days after 
tumor inoculation. Green line, the direction of tumor cross-sections. (b) Histological sections 
stained with hematoxylin and eosin showing local growth of the HCT-116-GFP tumor in the 
submucosal layer of the rectum (green arrowheads). Scale bar, 500 µm. Left, × 40 
magnification; middle, detail of the boxed region of the left panel, × 400; right, lymphatic 
vessel invasion of HCT-116-GFP cancer cells (yellow arrowheads), ×400 magnification. (c) 
Gross appearance of the abdominal cavity in a representative mouse. Seven days after 
inoculation of HCT-116-GFP cancer cells, mice were assessed for lymph node metastasis at 
laparotomy. The white box outlines the region shown in (d). (d) Left, four para-aortic lymph 
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nodes (LN) were identified (yellow arrows). Right, a sentinel node was positive for a light 
emitting spot with GFP fluorescence expressed by HCT-116-GFP cells under the 
fluorescence imaging (white arrowhead). Scale bar, 5 mm. 
 
Figure 3 Lymphatic spread of the virus and selective replication in metastatic foci in 
regional lymph nodes. Mice bearing HCT-116-RFP primary rectal tumors that developed 
lymph node metastasis were peritumorally injected with 1 × 10
8
 PFU of GFP-expressing 
OBP-401 into the submucosal space of the rectum. Virus spread and replication were 
assessed at laparotomy 6 days after virus administration. Three mice used for this study and 
analyses of a representative mouse are shown. (a) Gross localization of tumor-derived RFP 
and virus-induced GFP expression in the abdominal cavity of a representative mouse. The 
merged image shows that RFP-expressing metastatic foci in the sentinel lymph node were 
labeled with GFP fluorescence by OBP-401, indicating the successful delivery and 
replication of the virus in metastatic lymph nodes. Scale bars: 5 mm. (b) Excised metastatic 
lymph node of (A). Scale bar: 2 mm. (c) Histopathological examination of excised metastatic 
lymph nodes. Left, hematoxylin and eosin staining showing metastatic foci. Scale bar, 200 
µm; middle, detail of the boxed region of the left panel. Scale bar, 50 µm; right, 
immunohistochemical staining for adenoviral E1A protein in a serial section showing 
selective viral replication within tumor cells. The nuclei were counterstained with 
hematoxylin. Positive staining is reddish brown (yellow arrowheads). Scale bar, 50 µm. 
 
Figure 4 Biologically targeted ablation using OBP-301 eliminates metastatic foci on 
sentinel lymph nodes in an orthotopic colorectal cancer xenograft model. (a) Treatment and 
evaluation schedule of animal experiments. (b) Macroscopic and fluorescence images of the 
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abdominal cavity at laparotomy. Representative images among 7 or 8 mice with GFP-
expressing metastatic foci in regional lymph nodes on day 7 of tumor inoculation are shown 
(top panels). Following treatment with mock (PBS), dl312, cisplatin or OBP-301, the same 
mice were re-evaluated at laparotomy for the size and intensity of GFP signals on metastatic 
lymph nodes on day 14 (bottom panel). Scale bar, 5 mm (low magnification); 2 mm (high 
magnification).  
 
Figure 5 Quantitative analysis of the antitumor effect of OBP-301 on lymph node 
metastasis in an orthotopic colorectal cancer xenograft model. (a) The ratio of tumor cell-
derived GFP intensity on metastatic lymph nodes of HCT-116-GFP (left panel) or Colo205-
GFP (right panel) inoculated mice before and after the indicated treatments was calculated 
based on measurements of fluorescence images by using Image J software. We used 7 or 8 
mice with Colo205-GFP cells and 6 mice with HCT116-GFP cells for each treatment group. 
Data are means ± SD. Statistical significance was defined as p < 0.05 (single asterisk). (b) 
Mice with established orthotopic early HCT-116-GFP tumors were treated with submucosal 
injection of 1  109 PFU of OBP-301 or dl312 followed by primary rectal tumor dissection on 
day 7 after tumor inoculation. Three mice were used for each group. Lymph nodes were 
harvested on day 14, and DNA was then extracted and subjected to quantitative Alu PCR 
analysis. The number of metastatic tumor cells is defined as the Alu/GAPDH ratio relative to 
that of the mock (PBS)-treated sample (mock = 1). Data are shown as means ± SD. Statistical 
significance was defined as p < 0.05 (single asterisk). (c) A dose-dependent purging effect of 
OBP-301 on metastatic lymph nodes. Mice with orthotopic early HCT-116-GFP tumors 
received a submucosal injection of OBP-301 at the indicated MOIs on day 7 and were 
subsequently subjected to GFP image-based quantification of lymph node metastasis on day 
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14. The numbers of mice used in this experiment are 8 (mock) and 4 each (viral treatments).    
Data are shown as means ± SD. 
 
Figure 6 Virus-mediated biological elimination of established lymph node metastasis 
prevented relapse. (a) Gross and fluorescence images of the abdominal cavity were serially 
obtained at laparotomy on days 7, 14 and 35 after tumor inoculation in orthotopic HCT-116-
GFP tumor xenografts treated with PBS, dl312 or OBP-301. Representative images of each 
group are shown. Scale bar, 5 mm. (b) The GFP intensity of metastatic lymph nodes in each 
mouse was serially measured on days 7, 14 and 35. Data of each mouse are plotted 
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Supplementary Figure S1
Schematic DNA structures of the telomerase-specific viruses. (a) OBP-301 is a telomerase-
specific replication-competent adenovirus that contains the hTERT promoter sequence 
inserted into the adenovirus genome to drive transcription of the E1A and E1B bicistronic
cassette linked by an internal ribosome entry site. (b) OBP-401 is a variant of OBP-301in 
which the GFP gene is inserted into the E3 region, under the cytomegalovirus promoter for 
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In vitro cytopathic effect of OBP-301 on Colo205-GFP human colorectal cancer cells. 
Colo205-GFP cells were infected with dl312 or OBP-301 at an MOI of 10. Cell morphology 
and GFP expression were evaluated at the indicated time points by phase-contrast (top 
panels) and fluorescence (bottom panels) microscopy, respectively. Magnification:  200.





Procedure for inoculation of human colorectal cancer cells for establishment of a 
submucosally invaded orthotopic xenograft model. (a) The ano-rectal appearance of a 
representative mouse. (b) The ano-rectal wall was cut at a length of 7 mm to expose the 
dorsal rectal mucosa. (c) The human colorectal cancer cells were injected into the 
submucosal layer of the rectum. (d) After tumor cell inoculation, a bleb formed under the 
rectal mucosa at the site of injection. Scale bar, 5 mm.
Supplementary Figure S4
In vivo lymphatic spread of a blue dye in the regional lymph nodes.  (a) Gross appearance 
of the abdominal cavity. (b) The abdominal cavity was photographed 1 minute after 
injection of the indigo carmine blue dye into the submucosal space near the primary rectal 




Removal of the primary rectal tumor mimicking endoscopic submucosal dissection (ESD). 
(a) The ano-rectal appearance of a representative mouse a week after HCT-116-GFP tumor 
cell inoculation. Arrowheads indicate an established submucosally invaded rectal tumor. (b)
OBP-301 at a dose of 1109 PFU/30 μl PBS was peritumorally injected into the 
submucosal space before primary tumor dissection. White arrow, injection site. (c) The
primary rectal tumor was surgically removed using the submucosal dissection technique, 
which preserves the muscular layer of the rectum. Disappearance of GFP fluorescence 
indicated complete removal of the transplanted tumor tissues. Upper panel, bright view; 















Comparative study of OBP-301 and cisplatin effects in an orthotopic colorectal cancer 
xenograft model. Mice bearing HCT-116-GFP primary rectal tumors that developed lymph 
node metastasis were peritumorally injected with 30 μg of cisplatin or 1109 PFU of OBP-
301 into the submucosal space of the rectum. Gross (left panel) and fluorescence (right 
panel) images of the abdominal cavity were serially obtained at laparotomy on days 7, 14 
and 35 after tumor inoculation.
